14. Fluid Responsiveness & Hemodynamic Assessment

Quick Recap

Cross-cutting protocol — applies across shock states; cross-reference Vasopressor & Inotrope Selection & Titration (Cardiovascular System) for agent selection once the fluid-vs-vasopressor decision is made, and the Septic Shock (revised) and Sepsis Bundles & Source Control protocols (Infectious Diseases System) for the disease-specific resuscitation timeline this assessment framework feeds into. Addresses how to determine whether a patient will actually benefit from further fluid administration, and the current evidence on fluid strategy beyond the initial resuscitation bolus.

1. Definition

Fluid responsiveness: a physiological state in which a patient's stroke volume/cardiac output will meaningfully increase in response to a fluid bolus — typically operationalized as a ≥10–15% increase in stroke volume or cardiac output following a defined fluid challenge or equivalent maneuver. Critically, only approximately 50% of hemodynamically unstable critically ill patients are fluid responsive at any given assessment point — meaning a fluid bolus given without responsiveness assessment has, at best, a coin-flip chance of achieving its intended hemodynamic purpose, and administering fluid to a non-responsive patient provides no hemodynamic benefit while still carrying volume-related risk.

Static vs. dynamic measures: static measures (CVP, single-timepoint blood pressure) have been repeatedly shown to poorly predict fluid responsiveness and are no longer considered adequate as a sole basis for the fluid decision. Dynamic measures (pulse pressure variation, stroke volume variation, passive leg raise-induced changes, IVC ultrasound-based indices) assess the change in a hemodynamic parameter in response to a maneuver or the respiratory cycle, and are the current preferred approach — though each has specific validity conditions and limitations (Section 11).

The "after the first 1–3 L" decision: current evidence-based framing (from the CLOVERS trial specifically) of the recurring clinical fork in early sepsis resuscitation — having given an initial fluid bolus, should the clinician continue fluids to further augment preload, or transition to vasopressors to restore perfusion pressure? Current evidence indicates neither approach is clearly superior, reframing this as a genuine choice point requiring individualization rather than a a priori "correct" default beyond the initial bolus (Section 11).

2. Pathophysiology

Fluid responsiveness reflects Frank-Starling curve position: a patient on the steep, ascending portion of the curve will increase stroke volume substantially with added preload (fluid-responsive); a patient already on the flat portion of the curve (due to adequate or excessive preload, reduced ventricular compliance, or reduced contractile reserve) will not meaningfully increase stroke volume regardless of additional fluid — the fluid simply adds volume without functional benefit, and in this state, additional fluid contributes only to the risk side of the equation (interstitial edema, organ congestion) without the intended benefit.

Why static measures fail: CVP and similar single-timepoint pressures are influenced by ventricular compliance, intrathoracic pressure, valvular function, and many factors unrelated to volume status itself — a given CVP value does not reliably indicate where a patient sits on their individual Frank-Starling curve, which is why repeated large studies have found static measures poorly predictive despite their intuitive appeal and historical widespread use.

Why dynamic measures work (when their validity conditions are met): mechanically ventilated patients experience cyclic changes in intrathoracic pressure that transiently alter venous return and, in a fluid-responsive patient, correspondingly alter stroke volume with each ventilatory cycle — the magnitude of this cyclic variation (pulse pressure variation, stroke volume variation) reflects the same Frank-Starling-curve position that a fluid bolus itself would reveal, without actually having to give the fluid. Passive leg raise achieves a similar effect via a reversible, endogenous "auto-transfusion" of blood from the legs, allowing the same physiological question to be answered without any actual fluid administration — and, uniquely among dynamic measures, without depending on controlled mechanical ventilation or a specific tidal volume.

The physiological rationale for restrictive fluid strategies beyond initial resuscitation: prolonged, unguided liberal fluid administration in sepsis is associated with interstitial edema, impaired oxygen diffusion, organ congestion (particularly renal and pulmonary), and abdominal compartment physiology in severe cases — the biological plausibility for harm from excess fluid is well established, even though, as detailed in Section 11, this plausibility has not consistently translated into a demonstrated mortality benefit from restrictive strategies when tested in large RCTs.

3. Immediate Stabilization (ABCDE) — Fluid Responsiveness Assessment as Part of Circulation

Not a standalone acute stabilization scenario; this protocol's content is embedded within the Circulation component of shock management (cross-reference Vasopressor & Inotrode Selection & Titration and Septic Shock protocols):

Checklist:

4. Focused History

• Volume of fluid already administered (cumulative, not just the most recent bolus)
• Underlying cardiac function/reserve (affects both fluid tolerance and the reliability of certain dynamic measures)
• Rhythm (atrial fibrillation and other arrhythmias invalidate several pulse-pressure-based dynamic measures — Section 11)
• Ventilation status and settings (tidal volume, spontaneous breathing efforts affect the validity of ventilator-cycle-dependent dynamic measures)
• Abdominal pathology/intra-abdominal pressure (affects some IVC-based assessments)

5. Comprehensive System-wise Examination

• Cardiovascular: heart rate, blood pressure trend, peripheral perfusion (capillary refill, mottling — cross-reference Septic Shock protocol's ANDROMEDA-SHOCK-informed discussion of capillary refill as a resuscitation-guiding measure)
• Respiratory: signs of evolving pulmonary edema/fluid overload, particularly relevant when weighing further fluid administration
• Abdomen: distension/rigidity as both a differential consideration and a factor affecting IVC-based assessment validity

POCUS integration: central to this entire protocol — see Section 10.

6. Syndrome Identification — Reframed as Fluid-Responsiveness Classification

• Fluid responsive: further fluid administration likely to meaningfully increase cardiac output — reasonable to continue fluid resuscitation
• Not fluid responsive: further fluid unlikely to provide hemodynamic benefit — transition to or escalate vasopressor/inotrope support instead (cross-reference Vasopressor & Inotrope Selection & Titration protocol) rather than continuing fluid by default
• Indeterminate/measure not valid in this patient: e.g., arrhythmia present, spontaneous breathing efforts, low tidal volume ventilation — requires selecting an alternative, still-valid dynamic measure (Section 11) rather than defaulting to a static measure or abandoning assessment altogether

7. Differential Diagnosis — Not a Traditional Differential

This protocol's decision point is binary (responsive vs. not) rather than diagnostic; cross-reference the relevant shock-etiology protocol (Septic Shock, Cardiogenic Shock, Hypovolemic Shock, Obstructive Shock) for the underlying diagnostic differential driving the hemodynamic instability itself.

8. Severity/Risk Assessment

Not a severity scoring system; the relevant "assessment" is the fluid-responsiveness determination itself (Section 11), which functions as a real-time, repeatable decision tool rather than a static severity score.

9. Investigations

Immediate bedside: dynamic fluid-responsiveness assessment (Section 11) is itself the primary "investigation" in this protocol — performed via POCUS, arterial line waveform analysis, or other available modality per Section 11

Routine labs: lactate trend as an adjunct perfusion marker (cross-reference Septic Shock protocol's discussion of lactate's multifactorial drivers and appropriate interpretation alongside, not instead of, direct perfusion/responsiveness assessment)

10. Point-of-Care Ultrasound — Central to This Protocol

• IVC ultrasound: diameter and respiratory variability (collapsibility index in spontaneously breathing patients, distensibility index in mechanically ventilated patients) as a non-invasive fluid-responsiveness surrogate — useful but with recognized limitations (affected by intra-abdominal pressure, right heart function, and technique-dependent accuracy)
• Passive leg raise combined with echocardiographic stroke volume/velocity-time integral (VTI) assessment: elevating the legs 45° (or equivalent Trendelenburg-based maneuver) and measuring the resulting change in LVOT VTI or stroke volume via bedside echo — a reversible, repeatable, ventilator-mode-independent assessment, making it broadly applicable across patient types where other dynamic measures may not be valid
• LVOT VTI change with passive leg raise: increasingly used and studied as a preferred echocardiographic correlate, given the practicality of bedside ultrasound integration into this maneuver
• Cardiac POCUS more broadly: assessing for empty left ventricle, reduced LV end-diastolic area, or other qualitative signs of extreme hypovolemia (these specific echocardiographic criteria were explicitly used to define "extreme hypovolemia" triggering fluid administration in the CLOVERS trial's restrictive protocol arm, illustrating their practical clinical application)

11. Evidence-Based Management

Assessing Fluid Responsiveness — Choosing the Right Tool for the Right Patient

• Passive leg raise (PLR) combined with a direct cardiac output/stroke volume measure (echocardiographic VTI, pulse contour analysis, bioreactance, or end-tidal CO2 change) is broadly applicable across ventilation modes and rhythms — its key advantage is validity in spontaneously breathing patients and those with arrhythmias, where pulse-pressure-based dynamic measures are invalid
• Pulse pressure variation (PPV) / stroke volume variation (SVV): valid specifically in patients who are mechanically ventilated with a reasonable tidal volume, in sinus rhythm, without spontaneous breathing efforts — these validity conditions are frequently not met in real-world ICU patients (many are on low tidal volume lung-protective ventilation, have some spontaneous effort, or have arrhythmia), which is a genuine, common limitation of these otherwise well-validated measures
• End-tidal CO2 change with PLR: an emerging, less invasive surrogate correlating with cardiac output change, useful as a simple adjunct where more advanced monitoring is unavailable, though device- and technique-dependent accuracy remains an active area of study
• Restrictive fluid protocols in recent major trials (e.g., CLOVERS) have operationalized "extreme hypovolemia" using explicit combined criteria: IVC diameter <5 mm, an echocardiographically empty left ventricle (LV end-diastolic area index <5.5 cm²/m²), or a stroke-volume increase >30% with passive leg raise/fluid challenge/positive-pressure ventilation — a useful, evidence-derived practical framework for what "clearly still fluid responsive" looks like at the bedside

Fluid Strategy Beyond Initial Resuscitation — Genuine, Well-Studied Equipoise

• CLASSIC trial (Meyhoff et al., NEJM 2022, n=1,554, 31 ICUs, 8 European countries): patients with septic shock in the ICU randomized to a restrictive fluid strategy (further fluid only for specific, defined severe hypoperfusion criteria) vs. standard care — restrictive strategy resulted in a durable, meaningful reduction in fluid volume received (~2L less), but did not result in fewer deaths at 90 days compared to standard care; 90-day mortality was numerically lower in the restrictive group as an exploratory outcome, but this did not reach statistical significance
• CLOVERS trial (Shapiro et al., NEJM 2023, PETAL Network, unblinded superiority design): patients with sepsis-induced hypotension randomized to an early restrictive fluid + earlier vasopressor strategy vs. a liberal fluid strategy for the "after the first 1–3 L" decision specifically — no significant difference in mortality before discharge home by day 90 between the two strategies
• Systematic review of 11 RCTs (n=4,121): no significant difference between liberal and restrictive strategies in 30-day mortality (OR 0.73, 95% CI 0.30–1.80, p=0.50), adverse events, or hospital length of stay, though restrictive approaches showed trends toward reduced need for mechanical ventilation and fewer adverse events — directionally favorable but not statistically definitive
• Practical synthesis: neither a restrictive nor a liberal fluid strategy has been shown to be clearly superior for mortality in the post-initial-resuscitation phase of septic shock, across the two largest, most rigorous trials specifically designed to answer this question (CLASSIC, CLOVERS) plus supporting meta-analytic evidence. This represents genuine equipoise, not an unresolved methodological gap awaiting a future trial — an early vasopressor-prioritized, fluid-restrictive approach after the first 1–3 L is a defensible alternative, not a proven superior strategy, to continued liberal fluid administration. Individualization based on the patient's actual fluid-responsiveness phenotype (Section 6), rather than a uniformly applied restrictive or liberal protocol, is the most defensible current practice — this is precisely why dynamic fluid-responsiveness assessment (Section 10/11 above) matters more than picking a single strategy label to apply to all patients
• Some trial-design caveats worth noting: the CLASSIC trial's "standard care" comparator arm has been critiqued by some commentators as itself somewhat restrictive relative to broader real-world practice (receiving less fluid than, for example, the standard-care arms in earlier landmark early-goal-directed-therapy trials), which may have narrowed the observed between-group difference and limited the trial's ability to detect a true effect of a more liberal comparator

12. Organ Support

Directly interacts with Vasopressor & Inotrope Selection & Titration protocol — the fluid-responsiveness assessment in this protocol is the upstream decision point that determines whether the next step is further fluid or vasopressor escalation.

13. Disease-Specific Therapy — Not Applicable

This is an assessment/decision-framework protocol rather than a pharmacotherapy one.

14. Consultation Matrix

15. Monitoring Framework

• Clinical: reassess fluid responsiveness with each significant clinical change or before each additional fluid bolus beyond initial resuscitation, rather than treating an early assessment as fixed for the remainder of the resuscitation
• Cumulative fluid balance: tracked explicitly as its own metric, since cumulative volume (not just the most recent bolus decision) is what ultimately drives fluid-overload-related complications
• Escalation triggers: persistent hypoperfusion despite confirmed non-fluid-responsive status → escalate vasopressor/inotrope support rather than continuing fluid

16. ICU Bundle Checklist

17. Complications

Early:

• Fluid overload/interstitial edema from continued fluid administration to a non-responsive patient
• Pulmonary edema, worsening oxygenation
• Abdominal compartment syndrome in severe cases of cumulative fluid overload (cross-reference Abdominal Compartment Syndrome protocol, GI & Hepatology System)

Late:

• Prolonged mechanical ventilation and ICU stay associated with cumulative positive fluid balance
• Renal congestion contributing to worsening AKI in some cases

Prevention: dynamic fluid-responsiveness assessment before each fluid decision, individualized rather than protocol-uniform fluid strategy

Rescue: active fluid de-resuscitation once the acute resuscitation phase has passed (cross-reference Nutrition Support and Sepsis Bundles & Source Control protocols, both of which reference the emerging "resuscitate then de-resuscitate" two-phase model)

18. Escalation & De-escalation

Escalation: confirmed fluid-responsive state with ongoing hypoperfusion → continue judicious fluid administration; confirmed non-responsive state with ongoing hypoperfusion → escalate vasopressor/inotrope support (cross-reference Vasopressor & Inotrope Selection & Titration protocol) rather than further fluid.

De-escalation: resolving shock state with stable perfusion → transition toward the de-resuscitation phase, actively assessing for and correcting cumulative fluid overload rather than only monitoring passively.

19. ICU Discharge Criteria — Not Directly Applicable

Cross-reference ICU Discharge Criteria & Step-Down protocol for general discharge criteria; this protocol's relevance to discharge readiness is indirect, via its contribution to overall hemodynamic stability assessment.

20. Documentation & Medicolegal Checklist

• Fluid-responsiveness assessment method and result documented before significant fluid decisions beyond initial resuscitation
• Rationale for fluid vs. vasopressor escalation documented at each decision point
• Cumulative fluid balance tracked and documented
• POCUS findings supporting the responsiveness determination documented

21. Key Guidelines

• Current Surviving Sepsis Campaign guidance (cross-reference Septic Shock and Sepsis Bundles & Source Control protocols, both incorporating 2026 SSC updates) reflects the genuine equipoise on fluid strategy beyond initial resuscitation, supporting individualized, dynamically-assessed decision-making rather than a fixed volume protocol

22. Landmark Trials

23. Controversies

• Genuine equipoise, not an evidence gap: CLASSIC and CLOVERS are both large, rigorous, purpose-built trials that directly answered the restrictive-vs-liberal fluid question and found no clear winner — this should be communicated as settled equipoise (individualize based on physiology) rather than "more research is needed to determine the right strategy," since further large trials of a uniform strategy label are unlikely to resolve what appears to be genuine patient-level heterogeneity in optimal approach.
• CLASSIC's "standard care" comparator arm critique: some commentators have argued the standard-care fluid volumes in CLASSIC were lower than broader real-world practice (e.g., compared to earlier EGDT-era trials), potentially narrowing the observed between-group difference — worth being aware of as a genuine methodological consideration when interpreting the trial's generalizability to a specific local practice context.
• Validity condition limitations of PPV/SVV in real-world practice: the requirement for controlled mechanical ventilation, adequate tidal volume, sinus rhythm, and absence of spontaneous breathing efforts means these otherwise well-validated measures are frequently not applicable to the actual patient in front of the clinician — passive leg raise's broader applicability comes with its own practical burden (requires a direct cardiac output measurement device or technique to interpret, not just a blood pressure cuff), and no single dynamic measure is universally applicable across all ICU patients.
• Static measures (CVP) persist in practice despite the evidence: institutional habit and simplicity continue to drive some ongoing reliance on static measures despite the well-established evidence of their poor predictive value — a genuine practice-evidence gap worth actively addressing through protocol design and education.

24. References

1. Meyhoff TS, Hjortrup PB, Møller MH, et al; CLASSIC Trial Group. Restriction of intravenous fluid in ICU patients with septic shock. N Engl J Med. 2022;386(26):2459-2470.
2. Shapiro NI, Douglas IS, Brower RG, et al; National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network. Early restrictive or liberal fluid management for sepsis-induced hypotension (CLOVERS). N Engl J Med. 2023;388(6):499-510.
3. Abdelbaky AM, Elmasry WG, Awad AH. Restrictive versus liberal fluid regimen in refractory sepsis and septic shock: a systematic review and meta-analysis. Cureus. 2023;15(10):e47783.
4. Hernandez G, Ospina-Tascon GA, Damiani LP, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK randomized clinical trial. JAMA. 2019;321(7):654-664.
5. Douglas IS, Alapat PM, Corl KA, et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest. 2020;158(4):1431-1445.
6. Sepsis resuscitation: time to embrace a restrictive fluid strategy? [journal citation per source].
7. The Washington Manual of Critical Care, 4th ed. 2025 — hemodynamic monitoring chapter.
8. ICU Protocols: A Step-wise Approach, 2nd ed. — basics of echocardiography in the ICU chapter, ultrasound in ICU chapter.